Immune Modulation as a Treatment for Abdominal Aortic Aneurysms

S. Keisin Wang, Michael P. Murphy

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

In the United States, >200 000 new patients are diagnosed with abdominal aortic aneurysm (AAA) each year. Consequently, >40 000 highly morbid aortic reconstructions are performed each year to prevent aneurysm rupture, a catastrophic event associated with near-certain mortality. No pharmaceutical currently exists to slow aneurysm growth, but a 50% reduction in diameter growth per annum could halve the number of aortic reconstructions required. Therefore, successful use of cell therapy to modulate chronic inflammation hallmark to AAA to slow diameter expansion represents a potentially paradigmaltering treatment.

Original languageEnglish (US)
Pages (from-to)925-927
Number of pages3
JournalCirculation research
Volume122
Issue number7
DOIs
StatePublished - Mar 30 2018

    Fingerprint

Keywords

  • angiotensin II
  • aortic aneurysm, abdominal
  • doxycycline
  • matrix metalloproteinases
  • risk factors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this